Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Inspiratory Muscle Training in Patients With Heart Failure and Obstructive Sleep Apnea Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02794935
Recruitment Status : Unknown
Verified August 2016 by University of Cruz Alta.
Recruitment status was:  Recruiting
First Posted : June 9, 2016
Last Update Posted : August 9, 2016
Sponsor:
Collaborators:
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Information provided by (Responsible Party):
University of Cruz Alta

Brief Summary:
This research aims to evaluate the effects of inspiratory muscle training (IMT) on apnea hypopnea index, sleepiness, sleep quality, cognitive function, motor task, executive function, quality of life, chemoreflex sensitivity and vagal modulation of heart rate in patients with heart failure and obstructive sleep apnea syndrome.

Condition or disease Intervention/treatment Phase
Chronic Heart Failure Other: Inspiratory muscle training (IMT) Other: Sham IMT Not Applicable

Detailed Description:
Patients with heart failure will be selected through the Outpatient of the Rio Grande do Sul, for convenience. Subsequently, patients will be subjected to test respiratory muscle strength (manometer), respiratory muscle endurance, portable polysomnography, sleepiness, sleep quality, cognitive function (mini-mental state examination), motor task (execution of a sequence of digital movements), executive function, quality of life (SF-36), maximum exercise testing, chemoreflex sensitivity (peripheral chemoreflex by transient hypoxia and central chemoreflex by hypercapnic hyperoxia) and vagal modulation of heart rate (spectral analysis) before the start of the training protocol. Patients will be randomized to inspiratory muscle training or control group. Inspiratory muscle training will be performed for 30 minutes a day, 7 days a week, for 12 weeks with muscle training device (PowerBreathe). There will be a weekly monitoring in the Clinical Research Center of the institution where the maximal inspiratory pressure (MIP) and respiratory training techniques will be reassessed and readjusted (30% of MIP). The control group will be submitted to respiratory training techniques with muscle training device (PowerBreathe) without load. After this period, all initial tests will be reassessed. A group study with 15 heart failure patients without obstructive sleep apnea syndrome will be included.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effects of Inspiratory Muscle Training in Patients With Heart Failure and Obstructive Sleep Apnea Syndrome
Study Start Date : June 2016
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Inspiratory muscle training (IMT)
Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
Other: Inspiratory muscle training (IMT)
Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.

Placebo Comparator: Sham IMT
Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
Other: Sham IMT
Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center




Primary Outcome Measures :
  1. Apnea hypopnea index [ Time Frame: 12 weeks ]
    measured by portable polysomnography [in events/hour]


Secondary Outcome Measures :
  1. sleepiness [ Time Frame: 12 weeks ]
    measured by Epworth Sleepiness Scale [in score]

  2. sleep quality [ Time Frame: 12 weeks ]
    assessed by the Pittsburgh sleep quality index [in score]

  3. cognitive function [ Time Frame: 12 weeks ]
    measured by the mini-mental state [in points]

  4. motor task [ Time Frame: 12 weeks ]
    assessed by the execution of a sequence of digital movements [in time required and number of execution errors]

  5. executive function measured by Trail Making Test [ Time Frame: 12 weeks ]
    measured by Trail Making Test. In Part A, participants are asked to link numbered points randomly distributed on a sheet of paper in ascending order according to numbers. In Part B, the participants are asked to link numbers and letters alternately [in time of test performance, counts the number of errors, and calculates the difference in times: B-A.].

  6. quality of life assessed by the The Medical Outcomes Study - Short-form 36 (SF-36) [ Time Frame: 12 weeks ]
    assessed by the The Medical Outcomes Study - Short-form 36 (SF-36)

  7. peak oxygen consumption [ Time Frame: 12 weeks ]
    It will be assessed using of treadmill stress test with Bruce protocol. The peak oxygen consumption will be estimated according to the method established by the American College Sports Medicine [in mL.kg-1.min-1]

  8. chemoreflex sensitivity [ Time Frame: 12 weeks ]
    peripheral chemoreflex will be assessed by transient hypoxia [in L.min-1.mmHg] and central chemoreflex by hypercapnic hyperoxic in [L. min-1. %SatO2]

  9. vagal modulation measured by heart rate monitoring in the time domain (spectral analysis) [ Time Frame: 12 weeks ]
    measured by heart rate monitoring in the time domain by spectral analysis [in normalized units]



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Heart failure patients with obstructive sleep apnea- hypopnea
  • Heart failure patients without sleep apnea
  • Left ventricle fraction ejection < 51 % for men and < 53% for woman
  • Must be clinically stable
  • New York Heart Association I, II and III
  • Without changes in medication for the last three months.

Exclusion Criteria:

  • Unstable angina
  • Atrial fibrillation
  • Acute myocardial infarction (<6 months)
  • Recent heart surgery (<6 months)
  • Chronic metabolic disease
  • Infectious disease
  • Anemia
  • Severe hypoxemia
  • Neuromuscular disease
  • Diabetes mellitus
  • Obesity
  • Use of continuous positive airway pressure
  • Smoking
  • Pulmonary disease (forced vital capacity <80% of predicted and / or forced expiratory volume in one second <70% predicted).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02794935


Contacts
Layout table for location contacts
Contact: Carine C Callegaro, PhD 55 55 9914-6712 ccallegaro@unicruz.edu.br

Locations
Layout table for location information
Brazil
University of Cruz Alta Recruiting
Cruz Alta, Rio Grande do Sul, Brazil, 9800050
Contact: Carine C Callegaro       ccallegaro@unicruz.edu.br   
Sponsors and Collaborators
University of Cruz Alta
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Investigators
Layout table for investigator information
Principal Investigator: Carine C Callegaro, PhD University of Cruz Alta
Layout table for additonal information
Responsible Party: University of Cruz Alta
ClinicalTrials.gov Identifier: NCT02794935    
Other Study ID Numbers: CAAE: 25471413.7.0000.5322
First Posted: June 9, 2016    Key Record Dates
Last Update Posted: August 9, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The volunteers will receive the results of the evaluations pre and post-intervention by the of the study.
Keywords provided by University of Cruz Alta:
inspiratory muscle training
heart failure
obstructive sleep apnea
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiratory Aspiration
Heart Failure
Heart Diseases
Cardiovascular Diseases
Apnea
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Pathologic Processes